The European Medicines Agency safety committee has revisited the label and recommended the use of Janus kinase inhibitors in patients with certain risk factors only if no suitable treatment alternatives are available. Although regulatory decisions are key to place therapeutic options based on safety, broad restrictions might lead to unintended consequences without an individualized benefit–risk evaluation.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Winthrop, K. L. & Cohen, S. B. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat. Rev. Rheumatol. 18, 301–304 (2022).
European Medicines Agency. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. EMA https://www.ema.europa.eu/en/news/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic (2022).
US Food and Drug Administration. Janus kinase (JAK) inhibitors: drug safety communication - FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death. FDA https://www.fda.gov/safety/medical-product-safety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk# (2021).
Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316–326 (2022).
Olivera, P. A. et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 18, 857–873 (2021).
Solitano, V., D’Amico, F., Zacharopoulou, E., Peyrin-Biroulet, L. & Danese, S. Early intervention in ulcerative colitis: ready for prime time? J. Clin. Med. 9, 2646 (2020).
Hanauer, S. et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin. Gastroenterol. Hepatol. 17, 139–147 (2019).
Xiao, Y. et al. Effectiveness of tofacitinib for hospitalized patients with acute severe ulcerative colitis: case series. Dig. Dis. Sci. 67, 5213–5219 (2022).
Lasa, J. S., Olivera, P. A., Danese, S. & Peyrin-Biroulet, L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol. Hepatol. 7, 161–170 (2022).
Straatmijer, T. et al. Superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF-experienced ulcerative colitis patients: a nationwide Dutch registry study. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/J.CGH.2022.04.038 (2022).
S.D. has served as a speaker, consultant and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor. V.J. has received consulting/advisory board fees from AbbVie, Alimentiv Inc, Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, AstraZeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Metacrine, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso pharmaceuticals, Takeda, Teva, Topivert, Ventyx and Vividion, and speaker’s fees from Abbvie, Ferring, Bristol Myers Squibb, Galapagos, Janssen Pfizer Shire, Takeda and Fresenius Kabi. L.P.-B. reports personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher, ONO Pharma, Mopac, Cytoki Pharma, Morphic, Prometheus and Applied Molecular Transport. V.S. declares no competing interests.
Rights and permissions
About this article
Cite this article
Danese, S., Solitano, V., Jairath, V. et al. Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance. Nat Rev Gastroenterol Hepatol 20, 129–130 (2023). https://doi.org/10.1038/s41575-022-00722-7